Andrea Cercek, MD
Enriched profileSection Head, Colorectal Cancer; Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers; Ford Family Chair · Memorial Sloan Kettering Cancer Center
Andrea Cercek is Section Head, Colorectal Cancer; Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers; Ford Family Chair at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 592 publications with 33,805 citations (h-index 62); ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Andrea Cercek, MD, is Section Head, Colorectal Cancer at Memorial Sloan Kettering Cancer Center. The public record shows 592 publications with 33,805 citations (h-index 62), centered on Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cholangiocarcinoma and Gallbladder Cancer Studies. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 18 companies, 4 NIH-funded awards (2020–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Colorectal Cancer Treatments and Studies
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 149.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 27 Aug 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20256 payments
- PFIZER INC.Program year20254 payments
- GENZYME CORPORATIONProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.5%Nucleoside Analog Antiviral34.5%Lonsurf100%Part D<11 patientsCardiovascular
23.6%Calcium channel blocker23.6%Amlodipine Besylate100%Part D<11 patientsNervous system
21.8%Phenothiazine21.8%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
Sloan-Kettering Inst Can Research
FY2026$402,600R01CA288880 - Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer
Sloan-Kettering Inst Can Research
FY2025$1,224,361U01CA271287 - Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
Sloan-Kettering Inst Can Research
FY2025$402,600R01CA288880
Congress activity
Updated 27 Aug 2026
142 congress contributions (2010–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Alliance A022104/NRG-GI010, a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC): The Janus Rectal Cancer trial.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.
Clinical cancer research
Article2026 - Tumor microbial burden drives immune responses through regulation of Interferon signaling.
Cancer discovery
Article2026 - Molecular lineages of sporadic mismatch-repair deficient colorectal cancer.
Clinical cancer research
Article2026 - Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Colorectal cancer statistics, 20205,130 citations2020
- 02Colorectal cancer statistics, 20233,814 citations2023
- 03
- 04Immunotherapy in colorectal cancer: rationale, challenges and potential2,029 citations2019
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/AndreaCercek
- LinkedIn
linkedin.com/in/andrea-cercek-1567b5100
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Doximity
doximity.com/pub/andrea-cercek-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Instagram
instagram.com/cycleforsurvival/p/C9iCUQJuqS2
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Instagram
instagram.com/memorialsloankettering/reel/DHmCWzGSWoo
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Residency
Internal Medicine, New York Presbyterian/Weill Cornell Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Fellowship
Hematology/Oncology, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Section Head
Colorectal Cancer, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Co-Director
Center for Young Onset Colorectal and Gastrointestinal Cancers, MSK
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Contributor
The Cancer Letter
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancerletter.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Attending Physician
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- ASCO Post video interview
2024 ASCO Annual Meeting: durable complete responses to PD-1 blockade in rectal cancer
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center